Skip to main content
Erschienen in: World Journal of Urology 5/2013

01.10.2013 | Original Article

Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series

verfasst von: Sabine Brookman-May, Matthias May, Vincenzo Ficarra, Manuela Christine Kainz, Karin Kampel-Kettner, Stephanie Kohlschreiber, Valentina Wenzl, Meike Schneider, Maximilian Burger, Wolf F. Wieland, Wolfgang Otto, Derya Tilki, Christian Gilfrich, Markus Hohenfellner, Sascha Pahernik, Thomas F. Chromecki, Christian Stief, Richard Zigeuner, Members of the CORONA (Collaborative Research On Renal Neoplasms Association) Project

Erschienen in: World Journal of Urology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the still controversially discussed prognostic role of preoperative platelet level (PPL) and thrombocytosis (TC) in patients who undergo surgery for renal cell carcinoma (RCC) based on the largest patient series reported to date.

Methods

A total of 3,139 patients, who underwent radical or nephron-sparing nephrectomy at four centres, were subdivided based on a threshold for preoperative platelets of 400 × 109 cells/L. Univariate and multivariable Cox regression analyses were applied to determine the prognostic influence of PPL and TC on cancer-specific survival (CSS) for patients with localized and metastatic disease at presentation.

Results

Group 1 (PPL ≤ 400/nl) and Group 2 (PPL > 400/nl) included 2,862 (91 %) and 277 patients (9 %), respectively. With a median follow-up (FU) of 69.5 months (IQR: 35–105), CSS of all patients after 5 years was 84.6 % in Group 1 versus 53.4 % in Group 2 (p < 0.001). At multivariable analysis, TC (HR:1.337; p = 0.007) and continuous PPL (HR:1.001; p = 0.002) independently predicted a decreased survival. However, integration of these parameters into multivariable models for the entire study group and for patients with localized tumours did only result in marginal improvement of the model quality (0.66 and 1.04 %, respectively). Interestingly, neither TC (p = 0.257) nor PPL (p = 0.132) significantly influenced survival in M1 patients.

Conclusions

Preoperative TC turned out an independent predictor for decreased CSS in patients undergoing surgery for localized RCC. However, significant improvement of multivariable models comprising standard clinical and pathological parameters by the inclusion of TC is not achieved. In metastatic disease, TC did not reveal an independent influence on CSS.
Literatur
1.
Zurück zum Zitat Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S et al (2011) The epidemiology of renal cell carcinoma. Eur Urol 60(4):615–621PubMedCrossRef Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S et al (2011) The epidemiology of renal cell carcinoma. Eur Urol 60(4):615–621PubMedCrossRef
2.
Zurück zum Zitat Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC et al (2011) Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol 59:18–23PubMedCrossRef Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC et al (2011) Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol 59:18–23PubMedCrossRef
3.
Zurück zum Zitat Ficarra V, Brunelli M, Cheng L, Kirkali Z, Lopez-Beltran A, Martignoni G et al (2010) Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol 58(5):655–668PubMedCrossRef Ficarra V, Brunelli M, Cheng L, Kirkali Z, Lopez-Beltran A, Martignoni G et al (2010) Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol 58(5):655–668PubMedCrossRef
4.
Zurück zum Zitat Kim HS, Kim WS, Park SH, Jung CW, Choi HY, Lee HM et al (2010) Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy. Urol Oncol 28(2):157–163PubMedCrossRef Kim HS, Kim WS, Park SH, Jung CW, Choi HY, Lee HM et al (2010) Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy. Urol Oncol 28(2):157–163PubMedCrossRef
5.
Zurück zum Zitat Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L et al (2009) A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 55:287–295PubMedCrossRef Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L et al (2009) A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 55:287–295PubMedCrossRef
6.
Zurück zum Zitat Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S et al (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55(5):1145–1153PubMedCrossRef Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S et al (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55(5):1145–1153PubMedCrossRef
7.
Zurück zum Zitat Nieswandt B, Hafner M, Echtenacher B, Männel DN (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59:1295–1300PubMed Nieswandt B, Hafner M, Echtenacher B, Männel DN (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59:1295–1300PubMed
8.
Zurück zum Zitat Suppiah R, Shaheen PE, Elson P, Misbah SA, Wood L, Motzer RJ et al (2006) Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107:1793–1800PubMedCrossRef Suppiah R, Shaheen PE, Elson P, Misbah SA, Wood L, Motzer RJ et al (2006) Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107:1793–1800PubMedCrossRef
9.
Zurück zum Zitat Brookman-Amissah S, Kendel F, Spivak I, Pflanz S, Roigas J, Klotz T et al (2009) Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma. BJU Int 103:1375–1380PubMedCrossRef Brookman-Amissah S, Kendel F, Spivak I, Pflanz S, Roigas J, Klotz T et al (2009) Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma. BJU Int 103:1375–1380PubMedCrossRef
10.
Zurück zum Zitat Karakiewicz PI, Trinh QD, Lam JS, Tostain J, Pantuck AJ, Belldegrun AS et al (2007) Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol 52:1428–1436PubMedCrossRef Karakiewicz PI, Trinh QD, Lam JS, Tostain J, Pantuck AJ, Belldegrun AS et al (2007) Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol 52:1428–1436PubMedCrossRef
11.
Zurück zum Zitat Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F et al (2006) Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175:859–863PubMedCrossRef Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F et al (2006) Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175:859–863PubMedCrossRef
12.
Zurück zum Zitat Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K (2007) Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 79:111–116PubMedCrossRef Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K (2007) Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 79:111–116PubMedCrossRef
13.
Zurück zum Zitat Wosnitzer M, Polland A, Hai Q, Hruby G, McKiernan J (2011) Role of preoperative platelet level in clinical and pathological outcomes after surgery for renal cortical malignancies. BJU Int 108:73–79PubMedCrossRef Wosnitzer M, Polland A, Hai Q, Hruby G, McKiernan J (2011) Role of preoperative platelet level in clinical and pathological outcomes after surgery for renal cortical malignancies. BJU Int 108:73–79PubMedCrossRef
14.
Zurück zum Zitat Cho DS, Kim SJ, Lee SH, Ahn HS, Kim YS, Kim SI (2011) Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. Korean J Urol 52:104–109PubMedCrossRef Cho DS, Kim SJ, Lee SH, Ahn HS, Kim YS, Kim SI (2011) Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. Korean J Urol 52:104–109PubMedCrossRef
15.
Zurück zum Zitat Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M (2006) Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 13:1365–1370PubMedCrossRef Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M (2006) Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 13:1365–1370PubMedCrossRef
16.
Zurück zum Zitat Patel A, Bhavan R, Somani B, Nabi G (2010) Correlation of percentage changes in platelet counts with recurrence rate following radical nephrectomy. Indian J Urol 26:183–187PubMedCrossRef Patel A, Bhavan R, Somani B, Nabi G (2010) Correlation of percentage changes in platelet counts with recurrence rate following radical nephrectomy. Indian J Urol 26:183–187PubMedCrossRef
17.
Zurück zum Zitat Göğüş C, Baltaci S, Filiz E, Elhan A, Bedük Y (2004) Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 63:447–450PubMedCrossRef Göğüş C, Baltaci S, Filiz E, Elhan A, Bedük Y (2004) Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 63:447–450PubMedCrossRef
18.
Zurück zum Zitat Inoue K, Kohashikawa K, Suzuki S, Shimada M, Yoshida H (2004) Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int J Urol 11:364–367PubMedCrossRef Inoue K, Kohashikawa K, Suzuki S, Shimada M, Yoshida H (2004) Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int J Urol 11:364–367PubMedCrossRef
19.
Zurück zum Zitat Lee SE, Byun SS, Han JH, Han BK, Hong SK (2006) Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU Int 98:1228–1232PubMedCrossRef Lee SE, Byun SS, Han JH, Han BK, Hong SK (2006) Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU Int 98:1228–1232PubMedCrossRef
20.
Zurück zum Zitat Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398–406PubMedCrossRef Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398–406PubMedCrossRef
21.
Zurück zum Zitat Greene FL, Gospodarowicz M, Wittekend C et al (2009) American joint committee on cancer (AJCC) staging manual, 7th edn. Springer, Philadalphia, PA Greene FL, Gospodarowicz M, Wittekend C et al (2009) American joint committee on cancer (AJCC) staging manual, 7th edn. Springer, Philadalphia, PA
22.
Zurück zum Zitat Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B et al (1997) The Heidelberg classification of renal cell tumors. J Pathol 183:131–133PubMedCrossRef Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B et al (1997) The Heidelberg classification of renal cell tumors. J Pathol 183:131–133PubMedCrossRef
23.
Zurück zum Zitat Fuhrman S, Lasky LC, Limas L (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663PubMedCrossRef Fuhrman S, Lasky LC, Limas L (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663PubMedCrossRef
24.
Zurück zum Zitat Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387PubMedCrossRef Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387PubMedCrossRef
25.
Zurück zum Zitat DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845PubMedCrossRef DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845PubMedCrossRef
26.
Zurück zum Zitat Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR et al (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543–550PubMedCrossRef Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR et al (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543–550PubMedCrossRef
27.
Zurück zum Zitat Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799PubMedCrossRef Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799PubMedCrossRef
28.
Zurück zum Zitat Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fischer AM et al (2009) Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 56:479–484PubMedCrossRef Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fischer AM et al (2009) Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 56:479–484PubMedCrossRef
29.
Zurück zum Zitat Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM (2000) Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96:4216–4221PubMed Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM (2000) Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96:4216–4221PubMed
30.
Zurück zum Zitat Salven P, Orpana A, Joensuu H (1999) Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5:487–491PubMed Salven P, Orpana A, Joensuu H (1999) Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5:487–491PubMed
31.
Zurück zum Zitat Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E et al (1996) Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93:10589–10594PubMedCrossRef Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E et al (1996) Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93:10589–10594PubMedCrossRef
Metadaten
Titel
Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series
verfasst von
Sabine Brookman-May
Matthias May
Vincenzo Ficarra
Manuela Christine Kainz
Karin Kampel-Kettner
Stephanie Kohlschreiber
Valentina Wenzl
Meike Schneider
Maximilian Burger
Wolf F. Wieland
Wolfgang Otto
Derya Tilki
Christian Gilfrich
Markus Hohenfellner
Sascha Pahernik
Thomas F. Chromecki
Christian Stief
Richard Zigeuner
Members of the CORONA (Collaborative Research On Renal Neoplasms Association) Project
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 5/2013
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-012-0931-0

Weitere Artikel der Ausgabe 5/2013

World Journal of Urology 5/2013 Zur Ausgabe

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.